A Drug-drug Interaction Study of Avapritinib and Midazolam

Sponsor
Blueprint Medicines Corporation (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT04908176
Collaborator
(none)
20
1
16

Study Details

Study Description

Brief Summary

A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) and other Advanced Solid Tumors

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) and Other Advanced Solid Tumors
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients with metastatic, unresectable GIST

Patients will receive 5 mg of midazolam orally on Day 1 and Day 18. Patients will receive avapritinib 300 mg, orally on Day 3 through Day 19.

Drug: Avapritinib
avapritinib tablets
Other Names:
  • BLU-285
  • Drug: midazolam
    midazolam syrup

    Outcome Measures

    Primary Outcome Measures

    1. maximum plasma concentration (Cmax) of midazolam [Day 1 and Day 18]

    2. time of maximum plasma concentration (tmax) of midazolam [Day 1 and Day 18]

    3. area under the plasma concentration-time curve (AUC) of midazolam [Day 1 and Day 18]

    Secondary Outcome Measures

    1. Number of adverse events (AEs), serious AEs (SAEs), [up to approximately 2 months]

    2. Cmax at steady state (Cmax, ss) of avapritinib [Day 18]

    3. Cmax at steady state (Cmax, ss) of metabolite [Day 18]

    4. area under the plasma concentration-time curve at steady state (AUC,ss) of avapritinib [Day 18]

    5. area under the plasma concentration-time curve at steady state (AUC,ss) of metabolite [Day 18]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Must be ≥18 years of age at the time of signing the informed consent

    2. Confirmed diagnosis of

    • metastatic or unresectable KIT mutant GIST that has recurred or progressed after at least 4 lines of prior systemic SOC therapy or the Investigator has determined that treatment with SOC therapy is not appropriate for patients who failed at least 2 lines of prior SOC

    OR

    ---Non-resectable advance solid tumor with KIT mutation with progression following standard of care treatment.

    OR

    ---Confirmed diagnosis of recurrent or unresectable CNS tumors including :IDH-mutant astrocytoma, IDH-mutant oligodendroglioma, glioblastoma, H3K27-altered diffuse midline glioma, H3G34-mutant diffuse hemispheric glioma, midline glioma (with unknown H3K27 mutation status) that has failed prior radiation or systemic SOC therapy.

    1. Must be able to swallow an oral medication

    2. Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

    3. Patient agrees to use contraception consistent with local regulations

    4. Must provide signed informed consent to participate in the study

    Exclusion Criteria:
    1. Patients with GIST that harbors a known PDGFRA mutation

    2. Known hypersensitivity to avapritinib, midazolam, or any of their excipients

    3. Have received previous therapy with avapritinib

    4. Have any of the following laboratory abnormalities before the first dose of study drug:

    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >3 × upper limit of normal (ULN) if no hepatic metastases are present; >5 × ULN if hepatic metastases are present

    • Total bilirubin >1.5 × ULN; >3 × ULN in the presence of Gilbert's Disease

    • Estimated (Cockcroft-Gault formula) or measured creatinine clearance <60 mL/min

    • Platelet count <100 × 109/L

    • Absolute neutrophil count (ANC) <1.0 × 109/L

    • Hemoglobin <9 g/dL. Transfusion and erythropoietin may be used to reach at least 9 g/dL but must have been administered at least 2 weeks before the first dose of the study drug.

    1. Require therapy with a concomitant medication that is a strong and moderate CYP3A4 inhibitors or inducers

    2. Consumption of any nutrients known to modulate CYP3A4 enzymes activity (eg, grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville [blood] orange and derivative products, cruciferous vegetables [eg, broccoli, cauliflower, cabbage, brussel sprouts]) within 14 days before screening and during the study until the end of the Main Treatment Period

    3. Have received a prior anticancer drug less than 5 half-lives or 14 days (whichever is shorter) before screening

    4. Have had a major surgical procedure within 14 days of the first dose of study drug or have significant traumatic injury within 28 days before screening

    5. Have history of a cerebrovascular accident or transient ischemic attacks within 1 year before screening

    6. Have known risk of intracranial bleeding, such as a brain aneurysm or history of subdural or subarachnoid bleeding

    7. Have corrected QT interval using Fridericia's formula (QTcF) >450 msec

    8. Have clinically significant, uncontrolled, cardiovascular disease, including congestive heart failure Grades 2, 3, or 4 according to the New York Heart Association classification, myocardial infarction, or unstable angina within the previous 6 months, or uncontrolled hypertension

    9. Have experienced any hemorrhage or bleeding event National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade ≥3 within 4 weeks before screening. Exceptions are patients with primary CNS tumors who are eligible if the Grade ≥3 bleeding event was in the CNS and it occurred 2 weeks or more prior to the first dose of avapritinib.

    10. Patients who have a symptomatic nonhealing wound, ulcer, GI perforation, or bone fracture

    11. Have received organ or allogenic bone marrow or peripheral blood stem cell transplant

    12. Have known diagnosis of human immunodeficiency virus infection or active viral hepatitis; viral testing is not required

    13. History of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 14 grams of alcohol). Alcohol consumption will be prohibited 48 hours before screening and throughout the entire the Main Treatment Period

    14. Use of tobacco- or nicotine-containing products within 3 months of enrollment

    15. Is a female patient who is unwilling, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of informed consent and for until at least 6 months after the last dose of study drug. Males who are unwilling, if not surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of informed consent and for at least 90 days after the last dose of study drug.

    16. Is a female patient who is pregnant, as documented by a serum beta human chorionic gonadotropin (β-hCG) pregnancy test consistent with pregnancy obtained within 7 days before the first dose of study drug. Patients with β-hCG values that are within the range for pregnancy but are not pregnant (false positives) may be enrolled with written consent of the Sponsor after pregnancy has been ruled out. Females of nonchildbearing potential (postmenopausal for more than 12 months, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) do not require a serum β-hCG test.

    17. Female who is breastfeeding

    18. Have a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the Investigator's opinion, could affect the safety of the patient, alter the absorption, distribution, metabolism or excretion of the study drugs, or impair the assessment of study results.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Blueprint Medicines Corporation

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Blueprint Medicines Corporation
    ClinicalTrials.gov Identifier:
    NCT04908176
    Other Study ID Numbers:
    • BLU-285-1107
    First Posted:
    Jun 1, 2021
    Last Update Posted:
    Jul 22, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 22, 2022